Catalent Supports Eli Lilly's Growing Global Clinical Trials Needs with New Investment in Automated Packaging Solutions - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Catalent Supports Eli Lilly's Growing Global Clinical Trials Needs with New Investment in Automated Packaging Solutions

Source: Company News Release
Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that in support of the growth of its strategic partner, Eli Lilly, it is to install new automated prefilled syringe clinical packaging lines at its Philadelphia Clinical Supply Center of Excellence.

Catalent already has automated prefilled syringe packaging capabilities in its clinical supply facility in Schorndorf, Germany, providing end-to-end clinical supply solutions from clinical supply management, comparator sourcing and primary packaging to storage and distribution globally.

The packaging line is capable of the fully automated insertion of plunger rods, application of randomized and non-randomized labels and back-stop clips, and off-line labeling with booklet labels. This investment reflects a strong commitment from both Catalent and Eli Lilly to continue shared growth strategies, risks, and to build a long term strategic partnership.

“Our continued investments in clinical packaging, cold chain storage, digital solutions, and our expansion into China are all part of our growth strategy and commitment to our customers to help them reduce clinical trial timelines,” commented Gerry Hepburn, Chief Operating Officer, Vice President and General Manager of Catalent’s Clinical Supply Services business. “Our strategic partnership with Eli Lilly supports their innovation by bringing more products faster to market.”

For more information on Catalent’s Clinical Supply services, please visit: http://www.catalent.com/index.php/offerings/A-Z-Offerings/clinical-overview/clinical-supply-services

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here